Who makes BTA-C585 oral capsules?

BTA-C585 oral capsules is developed by Biota Pharmaceuticals, Inc..

What development phase is BTA-C585 oral capsules in?

BTA-C585 oral capsules is in Phase 1.

Last reviewed 2026-04-19 · How we verify

BTA-C585 oral capsules

Biota Pharmaceuticals, Inc. · Phase 1 active Small molecule

At a glance

Generic name	BTA-C585 oral capsules
Also known as	BTA585
Sponsor	Biota Pharmaceuticals, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety and Pharmacokinetics Study of Multiple Ascending Doses of BTA-C585 in Healthy Volunteers (PHASE1)
Safety, Efficacy and Pharmacokinetics of BTA-C585 in a RSV Viral Challenge Study (PHASE2)
Phase 1 Safety and Pharmacokinetics Study of Single Ascending Doses of BTA-C585 in Healthy Volunteers (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

BTA-C585 oral capsules CI brief — competitive landscape report
BTA-C585 oral capsules updates RSS · CI watch RSS
Biota Pharmaceuticals, Inc. portfolio CI